Taho Pharmaceuticals Ltd. (TPEX:6467)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
160.00
-1.50 (-0.93%)
At close: Dec 5, 2025
Market Cap 8.22B
Revenue (ttm) 7.78M
Net Income (ttm) -165.97M
Shares Out 51.39M
EPS (ttm) -3.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 166,228
Average Volume 325,453
Open 164.00
Previous Close 161.50
Day's Range 158.50 - 164.00
52-Week Range 32.25 - 208.50
Beta -61.78
RSI 42.75
Earnings Date Nov 13, 2025

About Taho Pharmaceuticals

Taho Pharmaceuticals Ltd., a pharmaceutical company, develops products using transdermal and transmucosal systems in Taiwan. The company’s portfolio includes TAH4411 Ondansetron ODF for the treatment of chemotherapy-induced nausea and vomiting; TAH3311 apixaban oral film, which is in phase 3 clinical trial for patients with Dysphagia; TAH3341 apixaban oral extend release film for patients with Dysphagia; TAH2211 Buprenorphine/Naloxone sublingual film, which is in phase 1 clinical trial for opioid addiction; TAH2231 Naloxone Buccal film , which ... [Read more]

Industry Pharmaceutical Preparations
Founded 2010
Employees 27
Stock Exchange Taipei Exchange
Ticker Symbol 6467
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.